BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31787726)

  • 21. Effects of ER stress on unfolded protein responses, cell survival, and viral replication in primary effusion lymphoma.
    Shigemi Z; Baba Y; Hara N; Matsuhiro J; Kagawa H; Watanabe T; Fujimuro M
    Biochem Biophys Res Commun; 2016 Jan; 469(3):565-72. PubMed ID: 26692493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The anti-malaria agent artesunate exhibits cytotoxic effects in primary effusion lymphoma.
    Ishikawa C; Mori N
    Invest New Drugs; 2021 Feb; 39(1):111-121. PubMed ID: 32885355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression Ratios of the Antiapoptotic BCL2 Family Members Dictate the Selective Addiction of Kaposi's Sarcoma-Associated Herpesvirus-Transformed Primary Effusion Lymphoma Cell Lines to MCL1.
    Dunham D; Viswanathan P; Gill J; Manzano M
    J Virol; 2022 Dec; 96(23):e0136022. PubMed ID: 36416587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altering the Anti-inflammatory Lipoxin Microenvironment: a New Insight into Kaposi's Sarcoma-Associated Herpesvirus Pathogenesis.
    Chandrasekharan JA; Huang XM; Hwang AC; Sharma-Walia N
    J Virol; 2016 Dec; 90(24):11020-11031. PubMed ID: 27681120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma.
    Caro-Vegas C; Bailey A; Bigi R; Damania B; Dittmer DP
    mBio; 2019 Feb; 10(1):. PubMed ID: 30782662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triptolide decreases expression of latency-associated nuclear antigen 1 and reduces viral titers in Kaposi's sarcoma-associated and herpesvirus-related primary effusion lymphoma cells.
    Long C; Guo W; Zhou H; Wang J; Wang H; Sun X
    Int J Oncol; 2016 Apr; 48(4):1519-30. PubMed ID: 26821279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.
    Qin Z; Dai L; Trillo-Tinoco J; Senkal C; Wang W; Reske T; Bonstaff K; Del Valle L; Rodriguez P; Flemington E; Voelkel-Johnson C; Smith CD; Ogretmen B; Parsons C
    Mol Cancer Ther; 2014 Jan; 13(1):154-64. PubMed ID: 24140934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of sulforaphane as a radiosensitizer for murine osteosarcoma cells.
    Sawai Y; Murata H; Horii M; Koto K; Matsui T; Horie N; Tsuji Y; Ashihara E; Maekawa T; Kubo T; Fushiki S
    Oncol Rep; 2013 Mar; 29(3):941-5. PubMed ID: 23254561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of c-Jun N-terminal kinase in G2/M arrest and caspase-mediated apoptosis induced by sulforaphane in DU145 prostate cancer cells.
    Cho SD; Li G; Hu H; Jiang C; Kang KS; Lee YS; Kim SH; Lu J
    Nutr Cancer; 2005; 52(2):213-24. PubMed ID: 16201852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma.
    Roy D; Dittmer DP
    Am J Pathol; 2011 Oct; 179(4):2108-19. PubMed ID: 21819957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.
    Bhatt S; Ashlock BM; Toomey NL; Diaz LA; Mesri EA; Lossos IS; Ramos JC
    J Clin Invest; 2013 Jun; 123(6):2616-28. PubMed ID: 23635777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.
    Bhatt AP; Bhende PM; Sin SH; Roy D; Dittmer DP; Damania B
    Blood; 2010 Jun; 115(22):4455-63. PubMed ID: 20299510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma.
    Paul AG; Sharma-Walia N; Chandran B
    PLoS One; 2011; 6(9):e24379. PubMed ID: 21980345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling.
    Mediani L; Gibellini F; Bertacchini J; Frasson C; Bosco R; Accordi B; Basso G; Bonora M; Calabrò ML; Mattiolo A; Sgarbi G; Baracca A; Pinton P; Riva G; Rampazzo E; Petrizza L; Prodi L; Milani D; Luppi M; Potenza L; De Pol A; Cocco L; Capitani S; Marmiroli S
    Oncotarget; 2016 Feb; 7(5):5521-37. PubMed ID: 26575168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma.
    Lu Z; Zhang Y; Xu Y; Wei H; Zhao W; Wang P; Li Y; Hou G
    Mol Biol Rep; 2022 Jan; 49(1):451-461. PubMed ID: 34731371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells.
    Uddin S; Hussain AR; Al-Hussein KA; Manogaran PS; Wickrema A; Gutierrez MI; Bhatia KG
    Clin Cancer Res; 2005 Apr; 11(8):3102-8. PubMed ID: 15837766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteasome inhibitor MG-132 mediated expression of p27Kip1 via S-phase kinase protein 2 degradation induces cell cycle coupled apoptosis in primary effusion lymphoma cells.
    Hussain AR; Ahmed M; Ahmed SO; Al-Thari S; Khan AS; Razack S; Platanias LC; Al-Kuraya KS; Uddin S
    Leuk Lymphoma; 2009 Jul; 50(7):1204-13. PubMed ID: 19557642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway.
    Wang L; Tian Z; Yang Q; Li H; Guan H; Shi B; Hou P; Ji M
    Oncotarget; 2015 Sep; 6(28):25917-31. PubMed ID: 26312762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV protease inhibitor Lopinavir induces apoptosis of primary effusion lymphoma cells via suppression of NF-κB pathway.
    Kariya R; Taura M; Suzu S; Kai H; Katano H; Okada S
    Cancer Lett; 2014 Jan; 342(1):52-9. PubMed ID: 24012878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular mechanisms of activating c-MET in KSHV+ primary effusion lymphoma.
    Lam BQ; Dai L; Li L; Qiao J; Lin Z; Qin Z
    Oncotarget; 2017 Mar; 8(11):18373-18380. PubMed ID: 28407694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.